[18F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction.
Published: 8th February 2018
Authors: T. Harustiak, M. Zemanova, P. Fencl, L. Hornofova, A. Pazdro, M. Snajdauf et al.
The aim of this prospective study was to assess whether [18F]fluorodeoxyglucose PET can be used to predict histopathological response early in the course of neoadjuvant chemotherapy in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.
Following the PET response criteria in solid tumours (PERCIST 1.0) as a standardized method for semiquantitative assessment of metabolic response, FDG‐PET/CT was performed before (PET1) and after (PET2) initiation of the first cycle of chemotherapy. The relative changes in the peak standardized uptake value (ΔSUL) and total lesion glycolysis (ΔTLG) between PET1 and PET2 were correlated with histopathological response, defined as less than 50 per cent viable tumour cells in the resection specimen. A receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut‐off value with the highest accuracy of histopathological response prediction.
PET2 was performed a median of 16 (range 12–22) days after the start of chemotherapy. Some 27 of 90 patients who underwent surgery had a histopathological response. There was no association between the median ΔSUL or median ΔTLG and the histopathological response. A
FDG‐PET/CT after the first cycle of chemotherapy does not predict histopathological response in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.Read more
You may also be interested in
Intrathoracic versus cervical anastomosis and predictors of anastomotic leakage after oesophagectomy for cancer.
Authors: J. A. H. Gooszen, L. Goense, S. S. Gisbertz, J. P. Ruurda, R. van Hillegersberg, M. I. van Berge Henegouwen et al.
Notes: Chest lower leak rates
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. BJS 2018; 105: 168-181.
Authors: A. T. Billeter, K. M. Scheurlen, P. Probst, S. Eichel, F. Nickel, S. Kopf et al.
Notes: Surgery is better
Health‐related quality of life after open transhiatal and transthoracic oesophagectomy for cancer. BJS 2018; 105: 230-236.
Authors: J. H. Kauppila, A. Johar, J. A. Gossage, A. R. Davies, J. Zylstra, J. Lagergren et al.
Notes: Favours transhiatal
Patient‐derived organoid models help define personalized management of gastrointestinal cancer. BJS 2018; 105: e48-e60.
Authors: M. R. Aberle, R. A. Burkhart, H. Tiriac, S. W. M. Olde Damink, C. H. C. Dejong, D. A. Tuveson et al.
Notes: Accelerating the science of personal care
Meta‐analysis of the prognostic value of CpG island methylator phenotype in gastric cancer. BJS 2018; 105: e61-e68.
Authors: A. G. M. T. Powell, S. Soul, A. Christian, W. G. Lewis
Notes: Heterogeneity in gene panels used
Authors: K. Boye, J.‐M. Berner, I. Hompland, Ø. S. Bruland, S. Stoldt, K. Sundby Hall et al.
Notes: Handle with care
Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer. BJS 2018; 105: e176-e182.
Authors: R. T. van der Kaaij, J. P. van Kessel, J. M. van Dieren, P. Snaebjornsson, O. Balagué, F. van Coevorden et al.
Notes: Frozen section of margins is key
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Comparison of gaze behaviour of trainee and experienced surgeons during laparoscopic gastric bypass. BJS 2018; 105: 287-294.
Authors: S. Erridge, H. Ashraf, S. Purkayastha, A. Darzi, M. H. Sodergren
Notes: Potential uses in training and assessment
Impact of weight loss and eating difficulties on health‐related quality of life up to 10 years after oesophagectomy for cancer.
Authors: P. Anandavadivelan, A. Wikman, A. Johar, P. Lagergren
Notes: Associated with deterioration of HRQOL
Influence of national centralization of oesophagogastric cancer on management and clinical outcome from emergency upper gastrointestinal conditions. BJS 2018; 105: 113-120.
Authors: S. R. Markar, H. Mackenzie, T. Wiggins, A. Askari, A. Karthikesalingam, O. Faiz et al.
Notes: Improves outcome of oesophageal perforation